AI in Bio Weekly Review: GSK Validates Chai's Zero-Shot Models, Iambic Sets $135M IPO Terms, and Matchpoint Secures $150M Series B — October 4–10, 2026
A defining week across computational biopharma: GSK expanded its enterprise collaboration with Chai Discovery after internal wet-lab testing confirmed zero-shot de novo binders across all evaluated targets, Iambic Therapeutics set terms for a $135M net Nasdaq IPO to advance brain-penetrant HER2 inhibitor IAM1363, Matchpoint Therapeutics closed a $150M Series B to bring its ML chemoproteomics covalent pipeline into the clinic, Eli Lilly committed up to $870M+ to expand its 'molecular gate' alliance with Gate Bioscience, Enliven Therapeutics secured FDA alignment on the pivotal Phase 3 ENABLE-2 design for relcobatinib in CML, and Caribou Biosciences halted its allogeneic CAR-T pipeline while cutting 90% of staff amid an off-the-shelf financing freeze.
Entering the second week of October 2026, the artificial intelligence and computational drug discovery sector witnessed a decisive maturation in how top-tier pharmaceutical developers deploy AI capital. If late September was defined by headline-grabbing megadeals and federal infrastructure mandates, the week of October 4–10, 2026 demonstrated the empirical reality of computational pharmacology: high-resolution generative models are directly replacing empirical wet-lab screening funnels, while public equity markets and venture syndicates are aggressively funding platform biotechs that possess bona fide clinical assets.
Leading the charge, British pharmaceutical major GSK deepened its multi-target discovery alliance with Chai Discovery after internal wet-lab evaluations verified that Chai’s generative models produced functional, high-affinity binders across every single target evaluated—achieved entirely zero-shot, without target-specific training. The move makes GSK the sixth global pharmaceutical company to integrate Chai’s platform in 2026, solidifying foundation-model-driven de novo molecular generation as a core industrial pillar.
Simultaneously, the public IPO window for clinical-stage AI platforms swung wide open. Following its initial Form S-1 registration statement reported in late September, San Diego-based Iambic Therapeutics formally set the terms for its Nasdaq initial public offering (ticker: IAM), targeting up to $135 million in net proceeds ($150 million gross) at an implied valuation of approximately $758 million to $800 million+. Crucially, the filing earmarks the vast majority of IPO proceeds directly for clinical trials—principally advancing its brain-penetrant HER2 inhibitor IAM1363 through Phase 1/2/3 development.
In private growth capital, Watertown-based Matchpoint Therapeutics raised an oversubscribed $150 million Series B financing co-led by Nextech Invest and Norwest, advancing its Advanced Covalent Exploration (ACE) platform and propelling lead oral T-cell modulator MPT-062 into clinical trials. Across Big Pharma business development, Eli Lilly doubled down on Gate Bioscience with an expansion package exceeding $870 million in bio-bucks, targeting extracellular disease proteins at the secretome bottleneck via oral small-molecule “molecular gates.”
In the clinic, Enliven Therapeutics (NASDAQ: ELVN) secured formal alignment with the U.S. FDA on the registrational design of its pivotal Phase 3 ENABLE-2 trial for relcobatinib (ELVN-001) in chronic myeloid leukemia (CML), setting up a head-to-head showdown against standard second-generation tyrosine kinase inhibitors before year-end.
Yet the week also delivered a stark reminder of biotechnology’s shifting capital tides: CRISPR pioneer Caribou Biosciences (NASDAQ: CRBU) announced the complete cessation of its allogeneic CAR-T pipeline—including lead asset vispa-cel—and initiated a 90% workforce reduction to explore strategic alternatives. The abrupt shutdown underscores a tectonic reallocation of capital away from logistically fraught ex vivo cell therapy manufacturing toward in vivo reprogramming, off-the-shelf molecular degraders, and conditioning-free modalities.
Below is our exhaustive, source-verified deep dive into the seven days that reshaped computational biopharma.
The Headlines at a Glance
┌──────────────────────────────────────────────────────────────────────────────────────────┐
│ WEEK IN REVIEW: OCTOBER 4 – OCTOBER 10, 2026 AT A GLANCE │
├──────────────────────┬───────────────────────────────┬───────────────────────────────────┤
│ Chai Discovery × GSK │ Multi-Target Enterprise Pact │ Zero-shot binders generated │
│ │ Wet-Lab Validation Complete │ across 100% of tested GSK targets;│
│ │ Chai-2 & Chai-3 Deployments │ 6th Big Pharma alliance of 2026 │
├──────────────────────┼───────────────────────────────┼───────────────────────────────────┤
│ Iambic Therapeutics │ Sets $135M Net Nasdaq IPO │ 9.375M shares at $15.00–$17.00; │
│ (NASDAQ: IAM) │ Terms (Form S-1/A Filed) │ $75M allocated to IAM1363 (HER2); │
│ │ Implied Valuation: ~$758M+ │ Funds operations into late 2028 │
├──────────────────────┼───────────────────────────────┼───────────────────────────────────┤
│ Matchpoint Tx │ $150M Series B Financing │ ACE Platform (ML + Chemoproteomics│
│ │ Nextech & Norwest Co-Lead │ Lead MPT-062 (oral T-cell │
│ │ Sanofi, Atlas, Access Backing │ modulator) enters clinic in 2027 │
├──────────────────────┼───────────────────────────────┼───────────────────────────────────┤
│ Eli Lilly × Gate Bio │ $870M+ Expansion Alliance │ Oral "Molecular Gate" mechanism; │
│ │ Sec61 Translocon Inhibition │ Blocks extracellular secretome │
│ │ Adds New Secretome Targets │ targets; expands July 2025 pact │
├──────────────────────┼───────────────────────────────┼───────────────────────────────────┤
│ Enliven Therapeutics │ FDA Phase 3 Alignment │ ENABLE-2 Trial (NCT study launch) │
│ (NASDAQ: ELVN) │ Relcobatinib (ELVN-001) │ ~450 2L+ CML patients vs. dasa/ │
│ │ BCR::ABL1 Selective Inhibitor │ nilo/bosutinib; MMR at Week 24 │
├──────────────────────┼───────────────────────────────┼───────────────────────────────────┤
│ Caribou Biosciences │ Allogeneic Pipeline Shelved │ Halts vispa-cel and CB-011; │
│ (NASDAQ: CRBU) │ 90% Headcount Layoff │ Capital freeze in ex vivo allo; │
│ │ Wedbush Financial Advisor │ Exploring M&A / asset sale │
└──────────────────────┴───────────────────────────────┴───────────────────────────────────┘1. GSK Validates Chai Discovery’s Zero-Shot Generative AI Models in Wet-Lab Assays, Signs Multi-Target Pact
On October 9, 2026, British multinational pharmaceutical company GSK and San Francisco-based foundation model pioneer Chai Discovery announced a multi-target discovery collaboration following an extensive internal wet-lab validation campaign (FierceBiotech).
The agreement marks a pivotal milestone for generative biomolecular design: rather than entering a partnership based on computational benchmarking on synthetic datasets, GSK subjected Chai’s algorithms to rigorous internal wet-lab verification across a blind panel of proprietary therapeutic targets.
The Wet-Lab Validation Campaign
Prior to executing the enterprise agreement, GSK challenged Chai Discovery’s platform with a diverse panel of undisclosed disease targets across its core therapeutic areas:
- Zero-Shot Generation: Chai’s models were tasked with generating binders completely zero-shot—meaning the algorithms were given only the target’s sequence and conformational structure without any target-specific fine-tuning, prior hit data, or evolutionary training on homologous binders.
- 100% Target Hit Rate: GSK expressed and purified the computationally designed candidates inside its own laboratories. Subsequent biophysical binding assays confirmed that Chai’s zero-shot designs successfully bound to every single target tested with nanometer-to-sub-nanomolar affinities and drug-like biophysical profiles.
- Integration with GSK Discovery Engine: Christopher Austin, M.D., Senior Vice President of R&D Technologies at GSK, confirmed the findings: “We evaluated their models across a panel of diverse targets and saw designs with strong binding affinities. Their technology complements our own internal models that we continuously retrain against our own wet-lab data, all helping to enable us to accelerate the discovery of potential new medicines.”
The Architectural Leap: From Chai-1 to Chai-3
Chai Discovery—co-founded in 2024 by Joshua Meier (former Meta AI and OpenAI researcher) alongside Jack Dent and a team from Stripe and OpenAI—has experienced one of the most explosive growth trajectories in modern TechBio:
- Chai-1 Foundation: Released openly in September 2024, Chai-1 established state-of-the-art multimodal predictions across protein-protein, protein-ligand, and protein-nucleic acid complexes, matching and in certain metrics exceeding AlphaFold 3.
- Chai-2 and Complex Epitopes: The company’s second-generation architecture achieved a 16% experimental hit rate in fully de novo antibody design in preprint disclosures and demonstrated the capacity to engineer conformational binders directly against six distinct G-protein coupled receptors (GPCRs).
- Chai-3 and Developability Co-Optimization: GSK is accessing Chai’s latest model family, Chai-3, which couples structural coordinate diffusion with active developability constraints, penalizing aggregation hotspots, hydrophobicity patches, and non-human immunogenicity motifs directly inside the generative sampling loop.
Big Pharma Enterprise Adoption
The GSK agreement represents Chai Discovery’s sixth major biopharma alliance within a nine-month period, following announced collaborations with Bristol Myers Squibb, Eli Lilly, Novartis, Pfizer, and argenx. Supported by a $400 million Series C closed in July 2026 that valued the startup at $3.8 billion, Chai has effectively established a cross-industry infrastructure layer for generative molecular design.
For GSK, the transaction operationalizes CEO Luke Miels’ stated strategic directive that the “number one priority for the usage of AI is the innovation dimension.” Coming on the heels of GSK’s $110 million cellular perturbation pact with Relation Therapeutics, the Chai alliance equips GSK with an automated discovery stack spanning high-content human cellular profiling to atomic-resolution zero-shot molecular design.
2. Iambic Therapeutics Sets Terms for $135M Net Nasdaq IPO to Fund Clinical Oncology Pipeline
On October 8, 2026, San Diego-based Iambic Therapeutics filed an amended Form S-1/A registration statement with the U.S. Securities and Exchange Commission, formally establishing pricing and share terms for its proposed initial public offering on the Nasdaq Global Market under the ticker symbol IAM (FierceBiotech; SEC Form S-1/A Filing).
Following its initial IPO intent disclosed in late September, Iambic’s definitive pricing terms offer the first concrete valuation metric for an AI-native small-molecule developer entering public markets since late 2023.
Offering Terms & Capital Architecture
- Share Count & Price Corridor: Iambic plans to offer 9,375,000 shares of common stock at a proposed price range of $15.00 to $17.00 per share.
- Gross & Net Proceeds: At the midpoint price of $16.00, the offering will generate $150.0 million in gross proceeds, yielding approximately $135.0 million in net proceeds after deducting underwriting discounts, commissions, and estimated offering expenses.
- Greenshoe Option: Underwriters have been granted a 30-day option to purchase up to an additional 1,406,250 shares, which would elevate net proceeds to $155.9 million.
- Implied Market Capitalization: At the $16.00 midpoint, Iambic’s implied market capitalization sits at approximately $758 million (and over $800 million on a fully diluted basis).
- Pro-Forma Balance Sheet: Combined with the $207.9 million in cash and cash equivalents reported on its balance sheet as of June 30, 2026, the IPO will provide Iambic with over $340 million in total liquid capital, extending its operational cash runway through the end of 2028.
Line-Item Use of Proceeds: Clinical Translation Over Hype
In an era where tech-heavy biotech filings often draw investor skepticism over open-ended compute expenditure, Iambic’s SEC filing provides an explicit, clinically weighted capital allocation:
┌──────────────────────────────────────────────────────────────────────────────────────────┐
│ IAMBIC THERAPEUTICS: IPO NET PROCEEDS ALLOCATION ($135M) │
├──────────────────────┬─────────────┬─────────────────────────────────────────────────────┤
│ Asset / Program │ Allocation │ Clinical Milestone / Development Objective │
├──────────────────────┼─────────────┼─────────────────────────────────────────────────────┤
│ IAM1363 (HER2/HER2) │ $75 Million │ Advance Phase 1 dose escalation; fund initiation of │
│ │ │ Phase 2 and registrational Phase 3 trials in brain │
│ │ │ metastases and HER2-altered solid tumors. │
├──────────────────────┼─────────────┼─────────────────────────────────────────────────────┤
│ IAM217 (KIF18A) │ $15 Million │ Advance brain-penetrant allosteric KIF18A inhibitor │
│ │ │ into first-in-human Phase 1 trials (TNBC / Ovarian).│
├──────────────────────┼─────────────┼─────────────────────────────────────────────────────┤
│ IAM-C1 (CDK2/CDK4) │ $15 Million │ Initiate Phase 1 clinical safety and PK evaluation │
│ │ │ in breast cancer and CCNE1-amplified malignancies. │
├──────────────────────┼─────────────┼─────────────────────────────────────────────────────┤
│ Molecular AI Stack │ $20 Million │ Scale training of Enchant v3 and NeuralPLexer │
│ │ │ physics-informed foundation models. │
├──────────────────────┼─────────────┼─────────────────────────────────────────────────────┤
│ Working Capital │ $10 Million │ General corporate operations and IND filings. │
└──────────────────────┴─────────────┴─────────────────────────────────────────────────────┘The Proprietary Assets
Co-founded in 2019 by Caltech chemical physics professor Tom Miller, Ph.D. (CEO), and University of Bristol theoretical chemist Fred Manby, Ph.D. (CTO), Iambic is building its public identity around three internally originated small-molecule assets:
- IAM1363: An oral, brain-penetrant small molecule designed to selectively inhibit wild-type and mutant HER2 while completely sparing EGFR. Conventional HER2 tyrosine kinase inhibitors (such as tucatinib or neratinib) suffer from narrow therapeutic indices due to wild-type EGFR inhibition (causing severe diarrhea and rash) or poor blood-brain barrier permeability. IAM1363 has demonstrated preliminary clinical central nervous system (CNS) antitumor activity with an exceptional tolerability profile in its ongoing Phase 1 trial.
- IAM217: A selective, CNS-penetrant allosteric inhibitor of KIF18A, an essential mitotic kinesin. The molecule targets chromosomal instability (CIN) in solid tumors, inducing selective mitotic arrest and apoptosis in aneuploid cancer cells while sparing diploid normal tissues.
- IAM-C1: A dual inhibitor of CDK2 and CDK4, rationally designed to overcome primary and acquired resistance to CDK4/6 inhibitors (such as palbociclib) in estrogen receptor-positive breast cancers.
With pricing anticipated during the week of October 12 and trading scheduled for mid-October, Iambic’s debut will serve as the primary public equity barometer for the computational biology sector heading into 2027.
3. Matchpoint Therapeutics Closes $150M Series B to Advance ML Chemoproteomics Covalent Pipeline into Clinic
On October 7, 2026, Watertown, Massachusetts-based Matchpoint Therapeutics announced the closing of an oversubscribed $150 million Series B financing round (FierceBiotech).
The round was co-led by premier life sciences crossover funds Nextech Invest and Norwest, with participation from new institutional investors including Invus, BB Biotech, the T1D Fund, and BOLD Longevity Growth. Founding backers Access Biotechnology and Atlas Venture, alongside Series A lead Sanofi Ventures and Digitalis Ventures, recommitted substantial capital. The round brings Matchpoint’s total equity raised to $220 million (plus $60 million in upfront partnership cash).
The Advanced Covalent Exploration (ACE) Platform
Targeting proteins with reversible, non-covalent inhibitors has left approximately 85% of the human proteome categorized as “undruggable”—plagued by shallow, featureless protein surfaces or fleeting, transient allosteric binding pockets.
Matchpoint’s Advanced Covalent Exploration (ACE) platform addresses this bottleneck through a closed-loop integration of machine learning and empirical chemoproteomics:
- Chemoproteomic Profiling at Scale: ACE screens vast, proprietary libraries of electrophilic small-molecule fragments directly in native human cell lysates. By utilizing activity-based protein profiling (ABPP), the platform maps precisely where electrophiles form stable, covalent bonds across thousands of native proteins simultaneously.
- Machine Learning Covalent Docking: High-dimensional chemoproteomic reactivity data trains deep generative graph networks and quantum mechanical covalent docking models. Rather than predicting passive shape complementarity, Matchpoint’s models predict the exact geometric trajectory and free energy barrier of covalent bond formation ($\Delta G^\ddagger$) between electrophilic warheads and nucleophilic amino acid residues (cysteine, lysine, histidine, and tyrosine).
- Sub-Proteome Selectivity: By computationally optimizing the reversible binding affinity of the small molecule scaffold before the covalent warhead engages, the ACE engine designs covalent inhibitors that exhibit zero off-target proteome reactivity, preventing the idiosyncratic toxicities that historically challenged first-generation covalent drugs.
Lead Asset: MPT-062
The Series B proceeds will be primarily directed toward advancing Matchpoint’s lead development candidate, MPT-062, into clinical proof-of-concept trials in 2027:
- First-in-Class Oral T-Cell Modulator: MPT-062 is a precision, orally bioavailable covalent small molecule engineered to modulate an essential, historically intractable target governing T-cell activation and pathogenic effector cytokine production in autoimmune and inflammatory disorders.
- Durable Target Engagement: Due to its covalent mechanism of action, MPT-062 achieves near-complete target saturation that persists long after systemic plasma concentrations have cleared. This pharmacodynamic decoupling enables once-daily or intermittent low-dose oral administration while mitigating systemic exposure.
- Pipeline Depth & Pharma Validation: Matchpoint is also advancing undisclosed covalent programs across immune-mediated inflammatory diseases. The company’s computational and chemical rigor was independently validated in 2025 through an exclusive multi-target licensing collaboration with Novartis, which provided $60 million in upfront cash to develop oral covalent inhibitors against an undisclosed master transcription factor.
In conjunction with the raise, Kanishka Pothula, Ph.D. (Managing Partner at Nextech Invest) and Brian Matesic, M.D. (Principal at Norwest) have joined Matchpoint’s Board of Directors, reinforcing the syndicate’s clinical steering capabilities as the company transitions into a clinical-stage developer.
4. Eli Lilly Expands “Molecular Gate” Drug Discovery Alliance with Gate Bioscience up to $870M+
On October 5, 2026, South San Francisco-based Gate Bioscience announced a significant multi-year expansion of its research and licensing collaboration with Eli Lilly and Company, potentially worth more than $870 million in research funding, upfront consideration, development milestones, and commercial royalties (BioSpace).
The deal expands an initial collaboration signed in July 2025 (valued at up to $856 million) and reflects Lilly’s aggressive institutional push into next-generation target destruction mechanisms beyond classical proteolysis-targeting chimeras (PROTACs) and molecular glues.
The “Molecular Gate” Paradigm: Gating the Sec61 Translocon
Approximately 30% of all human proteins—and a vast majority of the most validated disease drivers in immunology, oncology, neuroscience, and metabolic disease (including cytokines, chemokines, cell-surface receptors, and circulating hormones)—are synthesized and processed through the secretory pathway.
To exit the cell or integrate into the plasma membrane, these proteins must transit through a universal, highly conserved pore in the endoplasmic reticulum (ER) membrane: the Sec61 translocon channel.
┌──────────────────────────────────────────────────────────────────────────────────────────┐
│ THE MOLECULAR GATE MECHANISM OF ACTION (SEC61 CHANNEL) │
├──────────────────────────────────────────────────────────────────────────────────────────┤
│ 1. TARGET mRNA TRANSLATION: Ribosome translates secretory/membrane protein with signal. │
│ 2. CHANNEL ENGAGEMENT: Nascent protein engages the Sec61 translocon pore at the ER. │
│ 3. SELECTIVE GATING: Oral small-molecule "Molecular Gate" binds a transient pocket on │
│ the Sec61 complex, specifically blocking the transit of the TARGET protein while │
│ leaving thousands of other secretory proteins entirely unobstructed. │
│ 4. PRE-EMPTIVE DEGRADATION: Blocked at the ER gate, the nascent protein is shunted │
│ directly into ER-associated degradation (ERAD) and destroyed by cytoplasmic proteasomes│
│ before it can ever fold, secrete, or cause pathology. │
└──────────────────────────────────────────────────────────────────────────────────────────┘Historically, blocking the Sec61 translocon was deemed impossible due to toxicity: total channel blockade causes global ER stress, the unfolded protein response (UPR), and cellular apoptosis. Gate Bioscience’s breakthrough lies in discovering target-selective molecular gates—small molecules that interact with specific signal sequences or early conformational features of a single target protein, selectively shutting the translocon pore to that protein alone while permitting normal secretion of the remaining secretome.
Expanded Terms & Therapeutic Scope
- Target Expansion: The revised agreement adds one specific, high-priority therapeutic target to the collaboration, with an exclusive option for Lilly to nominate a second target.
- Commercial & Discovery Split: Gate Bioscience will lead early-stage discovery and molecular design using its proprietary Molecular Gate discovery engine. Lilly receives exclusive worldwide licenses to all resulting development candidates and will fully finance and execute IND-enabling toxicology, clinical development, regulatory filings, and global commercialization.
- Economics: Gate receives an undisclosed upfront cash payment, research funding, an exercise fee upon option trigger, and up to $870 million in cumulative preclinical, clinical, and commercial milestone payments, alongside tiered royalties on global product sales.
- Target Universe: Gate notes that among its platform’s addressable universe are over 4,000 secretome targets, including high-value pathogenic proteins in neurodegeneration, autoimmunity, and cardiometabolic disorders that currently lack approved therapies or can only be addressed with burdensome, chronic injectable biologics.
Founded in 2021 by CEO Jordi Mata-Fink, Ph.D., Gate collected a $65 million Series B in November 2025 led by Forbion with Lilly participating. With two consecutive multi-hundred-million-dollar deals executed with Lilly in fifteen months, Gate has positioned molecular gating as the leading alternative to intracellular degradation technologies.
5. Enliven Therapeutics Secures FDA Alignment on ENABLE-2 Phase 3 Design for Relcobatinib (ELVN-001)
On October 6, 2026, clinical-stage precision oncology company Enliven Therapeutics, Inc. (NASDAQ: ELVN) announced that it has reached formal regulatory alignment with the U.S. Food and Drug Administration (FDA) regarding the pivotal Phase 3 design of its ENABLE-2 clinical trial (PR Newswire).
The registrational trial will evaluate Enliven’s lead kinase inhibitor, relcobatinib (officially adopted by the USAN Council, formerly designated ELVN-001), in adults with previously treated chronic myeloid leukemia (CML).
Mechanistic Differentiation: Overcoming Off-Target Kinase Toxicity
CML is driven by the constitutively active BCR::ABL1 fusion oncogene. While first-generation (imatinib) and second-generation ATP-competitive tyrosine kinase inhibitors (TKIs; dasatinib, nilotinib, bosutinib) transformed CML from a fatal disease into a manageable condition, their clinical utility is severely limited by poor selectivity across the wider kinome:
- Off-Target Cardiovascular and Pleural Toxicities: Dasatinib potent inhibits SRC and TEC family kinases, driving pleural effusions and pulmonary arterial hypertension. Nilotinib potently inhibits PDGFR and VEGFR, resulting in severe peripheral arterial occlusive disease and ischemic cardiac events.
- Resistance Mutations: Acquired kinase domain mutations—particularly gatekeeper mutations like T315I—render standard second-generation agents ineffective.
- Relcobatinib’s Atomic Selectivity: Discovered using advanced structure-based drug design and molecular dynamics simulations, relcobatinib is a highly potent, ATP-competitive small-molecule inhibitor engineered to selectively target BCR::ABL1 while sparing SRC, TEC, PDGFR, and the broader kinome. In ongoing Phase 1 ENABLE evaluations, relcobatinib demonstrated deep molecular responses without inducing the class-defining cardiovascular or pulmonary toxicities seen with approved agents.
The Pivotal ENABLE-2 Phase 3 Architecture
With FDA alignment finalized, Enliven confirmed that ENABLE-2 is fully on track to initiate enrollment before the end of 2026:
- Patient Population: Approximately 450 adult patients with chronic-phase CML who have been previously treated with one or more prior TKIs (second-line and later; 2L+).
- Randomization & Comparators: Patients will be randomized 1:1 to receive either:
- Relcobatinib 80 mg orally once daily; or
- Investigator’s choice of standard second-generation TKI (dasatinib, nilotinib, or bosutinib).
- Primary Endpoint: Major Molecular Response (MMR; $BCR::ABL1^{IS} \le 0.1%$) at Week 24, providing a rapid, registrational efficacy readout.
- Key Secondary Endpoint: Durability of Major Molecular Response (MMR at Week 96), alongside safety, tolerability, event-free survival (EFS), and overall survival (OS).
Helen Collins, M.D., Chief Medical Officer of Enliven, highlighted the trial’s registrational power: “ENABLE-2 is designed to directly compare relcobatinib to the second-generation TKIs and evaluate its potential to be the best-in-class ATP-competitive inhibitor for patients with CML. We are encouraged by the enthusiasm from physicians and the broader CML community as we prepare to initiate the trial.”
By going head-to-head against established standard-of-care TKIs in a registrational setting, Enliven is attempting to position relcobatinib as the preferred backbone agent in 2L+ CML, challenging Novartis’s asciminib (Scemblix) and traditional ATP-competitive agents alike.
6. Caribou Biosciences Restructures, Halts Allogeneic CAR-T Pipeline, and Cuts ~90% of Workforce
In a stark contrast to the week’s capital influxes, Caribou Biosciences (NASDAQ: CRBU)—the CRISPR genome-editing pioneer co-founded by Nobel laureate Jennifer Doudna, Ph.D.—announced on October 6–7, 2026, that it is terminating its entire clinical-stage pipeline and slashing approximately 90% of its workforce while pursuing strategic alternatives (BioSpace).
The decision marks a watershed moment for the cell therapy sector, signaling the near-total capital exhaustion facing first-generation allogeneic (“off-the-shelf”) CAR-T approaches.
The Pipeline Halts: Vispa-cel and CB-011
Caribou confirmed that it is halting all further clinical development across its two proprietary clinical programs:
- Vispa-cel (formerly CB-010): An allogeneic anti-CD19 CAR-T cell therapy engineered using Cas12a chRDNA (CRISPR hybrid RNA-DNA guides) with a PD-1 genetic knockout to enhance persistence.
- Despite being awarded the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and reporting impressive Phase 1 ANTLER trial results in June 2026—including an 82% overall response rate (ORR), a 67% complete response rate (CR), and a median progression-free survival of 17.1 months in second-line large B-cell lymphoma without any graft-versus-host disease (GvHD)—the company could not secure the capital required to execute its planned Phase 3 ANTLER-3 study.
- CB-011: An allogeneic anti-BCMA CAR-T for relapsed/refractory multiple myeloma incorporating an immune-cloaking B2M knockout and HLA-E-peptide insertion, which was actively undergoing Phase 1 dose expansion.
Financial Realities & Strategic Review
- Workforce Reductions: Caribou is implementing a massive reduction affecting 87 of its 97 employees (covering nearly 90% of its staff), pursuant to California WARN notices. Restructuring charges are estimated at $15 million to $19 million.
- Cash Position: As of June 30, 2026, Caribou held $113.8 million in cash, cash equivalents, and marketable securities, which management had previously projected would fund operations through late 2027. However, the capital-intensive demands of building proprietary cell manufacturing facilities and launching registrational allogeneic trials proved insurmountable without external dilutive equity support.
- Financial Advisor Engaged: Caribou has engaged Wedbush Securities Inc. as its exclusive financial advisor to evaluate strategic alternatives, including a potential corporate merger, asset acquisition, out-licensing of its Cas12a and Cas12b chRDNA editing intellectual property, or outright sale of the company.
In an emotional statement, CEO Rachel Haurwitz, Ph.D., explained the economic rationale: “Caribou’s story has taken a heartbreaking turn. The decision reflects the difficult reality that the current financing environment for allogeneic CAR-T cell therapies has made it impossible to secure the capital required to responsibly advance them… This is an extraordinarily difficult decision, particularly because it is in no way a reflection of our belief that vispa-cel and CB-011 have the potential to benefit patients.”
Caribou’s restructuring crystallizes what industry leaders are calling the “allogeneic winter.” As clinical data has matured, complex ex-vivo cell engineering—burdened by intense lymphodepleting conditioning regimens, rejection kinetics, and massive cleanroom manufacturing overhead—has steadily lost investor enthusiasm to two competing paradigms: in vivo mRNA-encoded cell reprogramming (such as Novartis’s $7.8B bet on Abogen) and computationally optimized, conditioning-free autologous CAR-Ts (such as Generate Biomedicines’ GB-5267).
Notable Shorter Moves & Clinical Milestones
Click Therapeutics Wins Historic FDA 510(k) Clearance for Motivista (CT-155) in Schizophrenia
On October 5, 2026, New York-based Click Therapeutics announced that the U.S. FDA granted 510(k) clearance for Motivista (formerly CT-155), creating the first FDA-authorized treatment specifically indicated for the negative symptoms of schizophrenia in adults (ClinicalTrials.gov NCT05838625).
Indicated as an adjunct to clinician-managed outpatient care (including antipsychotics) in patients with clinically stable positive symptoms, Motivista provides a structured, 16-week digital therapeutic delivering adaptive cognitive behavioral therapy and social skills exercises.
In the pivotal Phase 3 CONVOKE trial (NCT05838625) evaluating 457 patients, Motivista demonstrated a statistically significant 6.8-point improvement in negative symptom severity on the CAINS-MAP (Clinical Assessment Interview for Negative Symptoms–Motivation and Pleasure) scale compared to 4.2 points in the digital control arm—a 62% relative improvement. Following Boehringer Ingelheim’s commercial rights handover to Click in April alongside a $50 million funding tranche, Click will now lead commercialization across U.S. health systems.
Ono Pharmaceutical Pays $80M Upfront for Regional Rights to Biohaven’s MoDE Pan-IgG Degraders
On October 8, 2026, Japan’s Ono Pharmaceutical and Biohaven Ltd. executed an exclusive regional licensing and collaboration agreement covering Biohaven’s proprietary MoDE (Molecular Degraders of Extracellular Proteins) pan-IgG degrader portfolio across Japan, South Korea, Taiwan, and ASEAN territories (FierceBiotech).
Under the terms of the agreement, Ono will pay Biohaven $80 million in upfront cash, an anticipated $20 million near-term milestone, and approximately 20% tiered royalties on net sales. The licensed portfolio is spearheaded by BHV-1300, an orally or subcutaneously administered autoinjector-delivered small-molecule degrader currently in Phase 3 trials for Graves’ disease, alongside next-generation assets BHV-1310 and BHV-1320.
Originating from David Spiegel’s laboratory at Yale University, the MoDE platform selectively binds pathogenic circulating IgG subclasses (IgG1, 2, and 4) and redirects them to the asialoglycoprotein receptor (ASGPR) on hepatocytes for rapid lysosomal degradation, providing an off-the-shelf, non-immunosuppressive alternative to FcRn antagonists and intravenous immunoglobulin (IVIG).
AbbVie’s c-Met ADC Telisotuzumab Adizutecan (Temab-A) Secures Dual FDA Breakthrough Therapy Designations
On October 7, 2026, AbbVie (NYSE: ABBV) announced that the U.S. FDA granted two Breakthrough Therapy Designations (BTDs) for its next-generation antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A; ABBV-400) (PR Newswire; ClinicalTrials.gov NCT05029882).
The first BTD covers Temab-A in combination with bevacizumab for adults with refractory, metastatic colorectal cancer (CRC). The second BTD recognizes Temab-A as monotherapy for EGFR wild-type, c-Met protein-expressing non-squamous non-small cell lung cancer (NSCLC) following platinum chemotherapy and anti-PD-(L)1 immunotherapy.
Engineered using AbbVie’s proprietary adizutecan platform, Temab-A couples an ultra-potent topoisomerase 1 inhibitor (Top1i) payload to a humanized bivalent IgG1 anti-c-Met mAb via a cleavable valine-alanine linker and stable bromoacetamide attachment, preventing premature payload release and expanding the therapeutic window across solid tumors.
2026 Nobel Prize in Chemistry Honors Stereoselective Asymmetric Synthesis and Autocatalysis
On October 7, 2026, the Royal Swedish Academy of Sciences awarded the 2026 Nobel Prize in Chemistry jointly to Henri B. Kagan and Kenso Soai for their foundational discoveries in asymmetric catalysis, nonlinear stereochemical effects, and asymmetric autocatalysis (STAT News).
The recognition holds profound resonance for contemporary computational biology: as AI generative chemistry models design increasingly complex, 3D chiral molecules, the ability of modern organic synthesis to selectively produce single enantiomers without racemic contamination traces back directly to Kagan’s nonlinear chiral amplification and the self-amplifying Soai reaction. Their discoveries provide the physical basis for modern automated robotic synthesis and high-throughput stereoselective hit validation in TechBio laboratories globally.
Strategic Analysis: The Three Paradigm Shifts of Mid-October 2026
Stepping back from isolated corporate announcements, the second week of October highlights three tectonic shifts redefining modern biopharma:
┌──────────────────────────────────────────────────────────────────────────────────────────┐
│ THE THREE PARADIGM SHIFTS OF MID-OCTOBER 2026 │
├──────────────────────────────────────────────────────────────────────────────────────────┤
│ 1. ZERO-SHOT GENERATIVE CHEMISTRY SUPPLANTS THE SCREENING FUNNEL │
│ • GSK's 100% wet-lab validation of Chai Discovery's models proves zero-shot binders │
│ can be designed de novo directly from target structures without assay cycles. │
│ • Big Pharma is transitioning from evaluating AI to embedding it at production scale. │
├──────────────────────────────────────────────────────────────────────────────────────────┤
│ 2. TARGET DESTRUCTION AT THE SOURCE: COVALENCE AND TRANSLOCON GATING │
│ • Beyond classical proteasomal PROTACs, the frontier of "undruggable" pharmacology │
│ is expanding into Sec61 translocon gating (Gate Bio/Lilly) and ML-guided chemoproteomics│
│ covalent modification (Matchpoint). │
│ • Prevents protein expression entirely or locks targets with irreversible affinity. │
├──────────────────────────────────────────────────────────────────────────────────────────┤
│ 3. THE ALLOGENEIC CELL THERAPY CONTRACTION & THE IN VIVO RESET │
│ • Caribou's 90% workforce reduction and pipeline wind-down crystallizes the severe │
│ financing freeze facing ex vivo allogeneic cell therapy. │
│ • Capital is re-routing toward in vivo mRNA reprogramming, conditioning-free CAR-Ts, │
│ and off-the-shelf targeted extracellular degraders. │
└──────────────────────────────────────────────────────────────────────────────────────────┘1. Zero-Shot Generative Chemistry Supplants the Screening Funnel
For decades, high-throughput screening (HTS) and DNA-encoded libraries (DEL) have formed the foundation of early discovery: synthesize hundreds of thousands of compounds, test them empirically against a target, and spend eighteen months humanizing or optimizing weak hits.
GSK’s wet-lab validation of Chai Discovery marks a decisive break from this paradigm. When a generative foundation model can output binders to diverse, blind targets that succeed zero-shot upon internal wet-lab synthesis, the fundamental unit of drug discovery shifts from empirical observation to computational inference. With Chai securing six top-pharma partnerships in nine months and Xaira revealing de novo antibody generation in under seven weeks, Big Pharma is no longer running exploratory pilots—it is actively redesigning its core discovery infrastructure around generative foundation models.
2. Covalent Chemistry and Translocon Gating Re-Open the Proteome
As the biopharma industry exhausted easily druggable kinases and receptor pockets, medicinal chemistry hit a plateau. This week illustrates how computational design is cracking the remaining proteome through two distinct biological choke points:
- Spatial Gating at the Endoplasmic Reticulum: Gate Bioscience and Eli Lilly’s $870M+ alliance proves that stopping a disease protein does not require binding an active site or recruiting a cytoplasmic E3 ligase after translation. By gating the Sec61 translocon pore, a small molecule can prevent an extracellular cytokine or receptor from ever entering the secretory pathway.
- Quantum-Informed Covalence: Matchpoint Therapeutics’ $150M raise shows that pairing machine learning with native chemoproteomics allows chemists to map transient, shallow allosteric pockets and lock them permanently with electrophilic covalent bonds. Instead of requiring picomolar non-covalent binding affinity, covalent engagement achieves near-permanent target inhibition with favorable pharmacokinetic half-lives.
3. The Allogeneic Cell Therapy Reckoning and Capital Reallocation
The contrast between Caribou Biosciences’ restructuring and the surrounding deal tape is the most telling lesson of October 2026. Caribou had exceptional science: Nobel-pedigree CRISPR technology, RMAT designation, an 82% response rate in lymphoma, and over $113 million in cash. Yet the sheer logistical burden of ex vivo cell therapy—viral vectors, specialized cleanroom apheresis facilities, cryopreservation chains, and the intense toxicity of lymphodepleting chemotherapy—has made off-the-shelf cell therapy economically and clinically uncompetitive in the current market.
Capital has not fled cellular and molecular medicine; it has simply evolved. The money that once funded ex-vivo allogeneic CAR-Ts is flowing directly into in vivo mRNA-LNP cell reprogramming (such as Novartis’s $7.8B bet on Abogen), conditioning-free cell engineering (Generate’s IL-18-armored GB-5267), and off-the-shelf extracellular degraders (Biohaven and Ono’s MoDE platform). Technologies that eliminate inpatient hospital stays and bespoke manufacturing are winning the macro allocation contest.
Summary of the Week’s Transactions & Clinical Milestones
| Company / Institution | Modality / Focus | Key Milestone / Deal Valuation | Clinical Trial ID / Status | Primary Source Verification |
|---|---|---|---|---|
| Chai Discovery / GSK | Generative Foundation Models / Structural AI | Multi-target discovery pact; wet-lab validated zero-shot binders across 100% of tested targets | Preclinical / Enterprise Deployment | FierceBiotech — GSK & Chai Discovery |
| Iambic Therapeutics (NASDAQ: IAM) | Quantum Machine Learning / Small Molecules | Set terms for $135M net ($150M gross) Nasdaq IPO; implied valuation ~$758M+; earmarks $75M for lead HER2 asset IAM1363 | SEC Form S-1/A Filing / Phase 1 | FierceBiotech — Iambic IPO Terms |
| Matchpoint Therapeutics | ML Chemoproteomics / Precision Covalent Drugs | Closed $150M Series B co-led by Nextech and Norwest; advances oral T-cell modulator MPT-062 | Clinical entry in 2027 | FierceBiotech — Matchpoint Series B |
| Gate Bioscience / Eli Lilly | Sec61 Translocon Inhibition / “Molecular Gates” | Expanded alliance up to $870M+ in bio-bucks; adds new targets to selectively block secretome egress | Preclinical / Discovery | BioSpace — Lilly & Gate Bioscience |
| Enliven Therapeutics (NASDAQ: ELVN) | Structure-Based Kinase Design / CML | Reached FDA Phase 3 alignment on ENABLE-2 study for relcobatinib (ELVN-001) vs. 2nd-gen TKIs | PR Newswire Alignment / Phase 3 launch 2026 | PR Newswire — Enliven ENABLE-2 |
| Caribou Biosciences (NASDAQ: CRBU) | CRISPR-Cas12a Editing / Allogeneic CAR-T | Halts clinical development of vispa-cel and CB-011; slashes 90% of staff; engages Wedbush for M&A/sale | Clinical Halt (ANTLER Phase 1 completed) | BioSpace — Caribou Restructuring |
| Click Therapeutics | Prescription Digital Therapeutics / AI-CBT | Received FDA 510(k) clearance for Motivista (CT-155); first treatment for negative schizophrenia symptoms | NCT05838625 (Phase 3 CONVOKE completed) | ClinicalTrials.gov CONVOKE Study |
| Ono Pharmaceutical / Biohaven | MoDE Extracellular Protein Degradation | $80M upfront ($20M milestone + 20% royalties) for Asian rights to Phase 3 Graves’ degrader BHV-1300 | FierceBiotech — Ono & Biohaven / Phase 3 | FierceBiotech — Ono Biohaven Deal |
| AbbVie (NYSE: ABBV) | c-Met Top1i Antibody-Drug Conjugates (ADC) | Granted two FDA Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A) in CRC and NSCLC | NCT05029882 (Phase 1/2 Study M21-404) | PR Newswire — AbbVie Temab-A BTD |
| Nobel Prize in Chemistry 2026 | Asymmetric Synthesis & Autocatalysis | Awarded to Henri B. Kagan and Kenso Soai for discoveries in chiral stereochemistry and nonlinear autocatalysis | Foundational Science | STAT News — 2026 Nobel Prize Chemistry |